Bengaluru-Based Lamark Biotech Raises Rs 6.5 Crore to Transform Biologic Therapies In a breakthrough moment for India’s biotech ecosystem, Lamark Biotech has secured Rs 6.5 crore in its
In a breakthrough moment for India’s biotech ecosystem, Lamark Biotech has secured Rs 6.5 crore in its pre-Series A funding round. The round, led by IAN Group—through funds like IAN Alpha and BioAngels—also saw participation from notable angel investors, including Dr. Vinayender Tulla, Dr. Nita Roy, and Venkataraman KNK, all experts in the life sciences domain.
Founded in 2018 by Dr. Vaibhav Bhatia, Lamark is addressing a pervasive challenge in the biologics market: reliance on cold-chain infrastructure. The company’s proprietary ProteoStrong platform is designed to stabilize fragile protein-based medicines—such as insulin, monoclonal antibodies, and therapeutic enzymes—without altering their essential structure. By reducing cold-chain dependency, Lamark aims to make critical treatments more accessible, affordable, and scalable—especially in regions with limited infrastructure.
“If it is not accessible, it is not a medicine,” emphasizes Bhatia, highlighting the startup’s mission to democratize access to safe and effective biologics.
Biologics—therapies derived from living organisms—are among the most effective treatments for chronic diseases, cancer, and autoimmune disorders. However, their global deployment is hampered by a strict requirement for storage and transport at low temperatures, typically 2–8 °C. Any temperature variation can significantly reduce potency, risking treatment efficacy and patient safety.
Lamark’s ProteoStrong platform offers a solution: a way to stabilize biologics to remain effective at higher temperatures—potentially room temperature—unlocking large new patient populations worldwide.
At the heart of Lamark Biotech lies its proprietary ProteoStrong technology, a breakthrough in molecular preservation. The platform uses novel protein excipients and nano-formulation methods to:
Essentially, ProteoStrong acts as a molecular shield—keeping fragile biologic drugs stable outside of refrigeration, without chemically modifying them.
With fresh capital and renewed momentum, Lamark is doubling down on its core programs:
Bhatia, who leads the company as CEO, states that scaling up thermostable insulin is now a top priority, along with applying the same stabilization technology to other therapeutics.
The Rs 6.5 crore investment round highlights the growing confidence among top-tier investors in Lamark’s potential. Padmaja Ruparel, Co-founder of IAN Group, explains:
“Investment in Lamark represents IAN’s investment strategy to grow innovations that solve real problems. Their thermostable biologics are critical in low-resource environments.”
By backing Lamark, IAN and its syndicate are not just betting on technology—they’re betting on a sustainable and equitable model of global healthcare.
By mitigating cold-chain restrictions, Lamark’s ProteoStrong platform could transform biologics delivery globally—making treatments more affordable, scalable, and reliable. Potential benefits include:
Lamark’s mission aligns with broader global health goals: democratizing access, ensuring equitable treatment, and innovating for underserved populations.
Transitioning from the lab to the shelf involves rigorous steps:
With funding secured, Lamark is now well-positioned to progress through these stages with strategic partners and expert backing.
Lamark Biotech’s journey reflects a broader trend in Indian biotech: a shift toward high-impact, tech-driven innovation in drug delivery, diagnostics, and therapeutics.
India now ranks among the top global biotech research centers—home to world-class talent, strong academic-industry ties, and venture capital investment. Lamark stands out as a prime example of this momentum, building breakthroughs rooted in real-world need.
As promising as Thermo-stable biologics sound, the path to success isn’t without hurdles:
Lamark’s ability to navigate these challenges will determine its eventual impact and success.
Lamark’s vision holds immense promise. By combining scientific innovation with an urgent need for pharma resiliency, the company aims to deliver:
If successful, Lamark could set a precedent—showing how biotech can be leveraged for both profitability and global good.
Lamark Biotech isn’t just another healthtech startup; it’s a mission-driven enterprise tackling one of biologics’ toughest challenges. With Rs 6.5 crore in fresh funding, industry veteran investors, and a breakthrough platform, the company is poised to make thermostable insulin—and potentially other biologics—a transformative reality.
By marrying innovation with equitable access, Lamark could redefine what it means for a medicine to truly become a medicine—reaching everyone, everywhere, safely and reliably.
